ATHEROSCLEROSIS-ASSOCIATED GENES

Abstract: The invention provides novel atherosclerosis-associated polynucleotides and polypeptides encoded by those genes. The invention also provides expression vectors, host cells, and antibodies. The invention also provides methods for screening or purifying ligands and diagnosing or treating atherosclerosis.

Description: ATHEROSCLEROSIS-ASSOCIATED GENES TECHNICAL FIELD The invenuon relates to 34 atherosclerosis-associated polynucleotides identified by their co- expression with known atherosclerosis genes and their corresponding gene products. The invenuon also relates to the use of these biomolecules in diagnosis, prognosis, prevention, treatment, and evaluation of therapies for diseases associated with atherosclerosis. BACKGROUND ART Atherosclerosis is a disorder charactenzed by cellular changes in the artenal inUma and the formation of artenal plaques containing intra- and extracellular deposits of lipids. The resultant thickening of artery walls and the narrowing of the arterial lumen is the underlying pathologic condition in most cases of coronary artery disease, aortic aneurysm, peπpheral vascular disease, and stroke. A cascade of molecules is involved in the cellular morphogenesis, proliferation, and cellular migration which results in an atherosclerotic lesion (Libby et al. (1997) Int J Cardiol 62.23-29). A healthy artery consists of three layers. The vascular intima, lined by a monolayer of endothe al cells in contact with the blood, contains smooth muscle cells in extracellular matrix An internal elastic lamina forms the border between the inUma and the tunica media. The media contains layers of smooth muscle cells surrounded by a collagen and elastin-πch extracellular matrix An external elastic lamina forms the border between the media and the adventitia The adventiUa contains nerves and some mast cells and is the ongin of the vasa vasorum which supplies blood to the outer layers of the tunica media Initiation of an atherosclerotic lesion often occurs following vascular endothehal cell injury as a result of hypertension, diabetes melhtus, hyper pidemia, fluctuating shear stress, smoking, or transplant rejection. The injury results in the local release of nitric oxide and superoxide anions which react to form cytodestructive peroxynitπte radicals, causing injury to the endothe um and myocytes of the intima. This cellular injury leads to the expression of a variety of molecules that produce local and systemic effects. The initial cellular response to injury includes the release of mediators of inflammation such as cytokmes, complement components, prostaglandins, and downstream transcnption factors. These molecules promote monocyte infiltration of the vascular intima and lead to the upregulation of adhesion molecules which encourage attachment of the monocytes to the damaged endothehal cells. Additionally, components of the extracellular matrix including collagens, fibπnogens, and matrix Gla protein are induced and provide sites for monocyte attachment. Annexins, plasminogen activator inhibitor 1 , and nitric oxide synthases are triggered to counteract these effects Monocytes that infiltrate the lesion accumulate modified low density lipoprotem lipid through scavenger receptors such as CD36 and macrophage scavenger receptor type I The abundance of modified hpids is a factor in atherogenesis and is influenced by modifying enzymes such as lipoprotem lipase, carboxyl ester lipase, serum amyloid P component, LDL-receptor related protein, microsomal triglyceride transfer protein, and serum esterases such as paraoxonase. Lipid metabolism is governed by cholesterol biosynthesis enzymes such as 3-hydroxy-3-methylglutaryl coenzyme A synthase, and products of the apohpoprotein genes. Modified lipid stabilization and accumulation is aided by penlipin and alpha-2-macroglobulιn. As monocytes accumulate in the lesion, they can rupture and release free cholesterol, cytokmes, and procoagulants into the surrounding environment. This process leads to the development of a plaque which consists of a mass of hpid-engorged monocytes and a pid-nch necrotic core covered by a fibrous cap. The gradual progression of plaque growth is punctuated by thrombus formation which leads to clinical symptoms such as unstable angina, myocardial infarction, or stroke. Thrombus formation is initiated by episodic plaque rupture which exposes flowing blood to tissue factors, which induce coagulation, and collagen, which activates platelets. After initiation of the atherosclerotic lesion, enzymes that degrade extracellular matrix components such as matrix metalloproteinases and cathepsin K are up-regulated, and their inhibitors are down-regulated. This results in destabilization of the atherosclerotic lesion and subsequent complications including myocardial infarction, angina, and stroke. Further artenal occlusion and infiltration increase with the expression of coagulation factors and down-regulation of their inhibitors, antithrombin III, and lipoprotein-associated coagulation inhibitor Smooth muscle cells build up in the artenal media and constitute one of the principal cell types in atherosclerotic and restenotic lesions. They show a high degree of plasticity and are able to shift between a differentiated, contractile phenotype and a less differentiated, synthetic phenotype. This modulation occurs as a response to factors secreted from cells at the site of vascular injury and results in structural reorganization with a loss of myofilaments and the formation of an extensive endoplasmic reticulum and a large Golgi complex. Genes encoding secreted protein, acidic and nch in cysteme (SPARC) and endothelιn-1 contnbute to these changes. At the same time, the expression of cytoskeletal proteins such as calponin, myosin, desmin, and other gene products m the cells is altered. As a result, the smooth muscle cells lose their contractility and become able to migrate from the media to the intima, to proliferate, and to secrete extracellular matnx components which contnbute to artenal mtimal thickening. The initiation and progression of atherosclerotic lesion development requires the interplay of vaπous molecular pathways Many genes that participate in these processes are known, and some of them have been shown to have a direct role in atherosclerosis pathogenesis by animal model expenments, in vitro assays, and epidemiological studies (Krettek et al. (1997) Arteπoscler Thromb Vasc Biol 17.2897-2903, Fisher et al. (1997) Atherosclerosis 135.145-159, Shin et al. (1998) Circulation 95.2684-2693; and Bocan et al- (1998) Atherosclerosis 139.21-30) The present invention satisfies a need in the art by providing new compositions that are useful for diagnosis, prognosis, treatment, prevention, and evaluation of therapies for diseases associated with atherosclerosis We have implemented a method for analyzing gene expression patterns and have identified 34 atherosclerosis-associated polynucleotides through their co-expression with 66 known atherosclerosis-associated genes SUMMARY OF THE INVENTION The invention provides for a substantially purified polynucleotide compnsing a gene that is coexpressed with one or more known atherosclerosis-associated genes in a biological sample Known atherosclerosis-associated genes include and encode human 22kDa smooth muscle protein, calponin, desmin, smooth muscle myosin heavy chain, alpha tropomyosin, human tissue inhibitor of metalloproteinase 3, human tissue inhibitor of metalloproteιnase-2, human tissue inhibitor of metalloproteιnase-4, pro alpha 1(1) collagen, collagen alpha-2 type I, collagen alpha-6 type I, procollagen alpha 2(V), collagen VI alpha-2, type VI collagen alpha3, pro-alpha- 1 type 3 collagen, pro- alpha- 1 (V) collagen, collagenase type IV/ matnx metalloproteinase 9/gelatιnase B, matrix Gla protein, cathepsin K, fibnnogen beta chain gene, fibnnogen gamma chain gene, pre-pro-von WiUebrand factor, coagulation factor 11/ prothrombin, coagulation factor XII, coagulation factor VII, platelet endothehal cell adhesion molecule, lipoprotem-associated coagulation inhibitor, antithrombin III vanant, plasminogen activator inhibitor- 1 , lipoprotem lipase, alpha-2-macroglobulιn, apolipoprotem Al, apo poprotein All, apolipoprotem B-100, lipoprotem apoCII, pre-apohpoprotein CIII, apolipoprotem apo C-IV, macrophage scavenger receptor type I, human antigen CD36 gene, serum amyloid P component, carboxyl ester lipase gene, paraoxonase 1, paraoxonase 2, paraoxonase 3, LDL-receptor related protein, hepatic tnglyceπde lipase, 3-hydroxy-3-methylglutaryl coenzyme A synthase, very low density lipoprotem receptor, microsomal tnglycende transfer protein, penlipm, endothehn-1, endothelin receptor A, interleukm 6, interleukm 1, complement protein C8 alpha, complement component C9, prostaglandm D2 synthase, annexin Il/lipocortinll, annexin I/lipocortin, prostaglandin-endoperoxide synthase 2, insulin-like growth factor binding protein- 1, secreted protein, acidic and nch in cysteine, human NF-kappa-B transcnption factor, angiotensinogen, nitric oxide synthase 3, and nitnc oxide synthase 2 The invention also provides a substantially punfied polynucleotide compnsing a gene that is coexpressed with one or more known atherosclerosis-associated genes in a plurality of samples In one aspect, the polynucleotide compπses a polynucleotide sequence selected from a polynucleotide encoding a peptide selected from SEQ ID NOs 1-34, a polynucleotide sequence complementary to the polynucleotide sequence of SEQ ID NOs 1-34. and a probe compnsing at least 18 sequential nucleotides of the polynucleotide sequence of SEQ ID NOs 1-34 or their complements The invention further provides a pharmaceutical composition compnsing a polynucleotide and a pharmaceutical earner. The invention additionally provides methods for using a polynucleotide. One method uses the polynucleotide to screen a library of molecules or compounds to identify at least one ligand which specifically binds the polynucleotide and comprises combimng the polynucleotide with a library of molecules or compounds under conditions to allow specific binding and detecting specific binding, thereby identifying a ligand which specifically binds the polynucleotide. In this first method, the library is selected from DNA molecules, RNA molecules, PNAs, mimetics, and proteins; and the ligand identified using the method may be used to modulate the activity of the polynucleotide. A second method uses the polynucleotide to punfy a ligand which specifically binds the polynucleotide and compnses combimng the polynucleotide with a sample under conditions to allow specific binding, detecting specific binding between the polynucleotide and a ligand, recovenng the bound polynucleotide, and separating the polynucleotide from the ligand, thereby obtaining punfied ligand. A third method uses the polynucleotide to diagnose a disease or condition associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a plurality of biological samples and comprises hybridizing a polynucleotide to a sample under conditions to form one or more hybπdization complexes, detecting the hybridization complexes, and comparing the levels of the hybπdization complexes with the level of hybndization complexes in a non-diseased sample, wherein the altered level of hybndization complexes compared with the level of hybndization complexes of a non-diseased sample indicates the presence of the disease or condition. A fourth method uses the polynucleotide to produce a polypeptide and compnses cultunng a host cell containing an expression vector containing the polynucleotide under conditions for expression of the polypeptide and recovenng the polypeptide from cell culture. The invention provides a substantially punfied polypeptide comprising the product of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a plurality of samples. The invenuon also provides a polypeptide compnsing a polypeptide sequence selected from the polypeptides encoded by SEQ ID NOs: 1-34 and an ohgopeptide sequence compπsing at least 6 sequential amino acids of the polypeptide sequence of encoded by SEQ ID NOs: 1-34 The further provides a polypeptide compnsing the amino acid sequence of SEQ ID NO.35. The invention still further provides a pharmaceutical composition compπsing a polypeptide and a pharmaceutical earner. The invention additionally provides methods for using a polypeptide. One method uses the polypeptide to screen a library of molecules or compounds to identify at least one ligand which specifically binds the polypeptide and compnses combimng the polypeptide with the library of molecules or compounds under conditions to allow specific binding and detecting specific binding between the polypeptide and ligand, thereby identifying a ligand which specifically binds the polypeptide. In this method, the library is selected from DNA molecules, RNA molecules, PNAs, mimetics, polypeptides, agonists, antagonists, and antibodies, and the ligand identified using the method is used to modulate the activity of the polypeptide. A second method uses the polypeptide to punfy a ligand from a sample and compnses combimng the polypeptide with a sample under conditions to allow specific binding, detecting specific binding between the polypeptide and a ligand, recovering the bound polypeptide, and separating the polypeptide from the ligand, thereby obtaimng punfied ligand. A third method uses the polypeptide to treat or to prevent a disease associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a subject m need and comprises administenng to the subject in need the pharmaceutical composition containing the polypeptide in an amount effective for treating the disease. The invenuon provides an antibody or Fab compπsing an antigen binding site, wherein the antigen binding site specifically binds to the polypeptide. The invention also provides a method for treating a disease associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a subject in need, the method compnsing the step of administenng to the subject in need the antibody or the Fab in an amount effective for treating the disease. The invention further provides an immunoconjugate compnsing the antigen binding site of the antibody or Fab joined to a therapeutic agent. The invention additionally provides a method for treating a disease associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a subject in need, the method compnsing the step of administering to the subject m need the immunoconjugate in an amount effective for treating the disease. BRIEF DESCRIPTION OF THE SEQUENCE LISTING The Sequence Listing provides exemplary atherosclerosis-associated gene sequences including polynucleotide sequences SEQ ID NOs: 1-34 and the polypeptide sequence, SEQ ID NO.35. Each sequence is identified by a sequence identification number (SEQ ID NO) DESCRIPTION OF THE INVENTION It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include the plural reference unless the context clearly dictates otherwise. For example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth. Definitions "Atherosclerosis-associated gene" refers to a gene or polynucleotide that exhibits a statistically significant coexpression pattern with known atherosclerosis-associated genes which are useful in the diagnosis, treatment, prognosis, or prevention of atherosclerosis. "Known atherosclerosis-associated gene" refers to a sequence which has been previously identified as useful in the diagnosis, treatment, prognosis, or prevention of atherosclerosis and includes polynucleotides encoding human 22kDa smooth muscle protein, calponin. desmin, smooth muscle myosin heavy chain, alpha tropomyosin, human tissue inhibitor of metalloproteinase 3, human tissue inhibitor of metalloproteinase-2, human tissue inhibitor of metalloproteinase-4, pro alpha 1(1) collagen, collagen alpha-2 type I, collagen alpha-6 type I, procollagen alpha 2(V), collagen VI alpha-2, type VI collagen alpha3, pro-alpha- 1 type 3 collagen, pro- alpha- 1 (V) collagen, collagenase type IV/ matrix metalloproteinase 9/gelatinase B, matrix Gla protein, cathepsin K, fibrinogen beta chain gene, fibrinogen gamma chain gene, pre-pro-von WiUebrand factor, coagulation factor Il/prothrombin, coagulation factor XII, coagulation factor VII, platelet endothehal cell adhesion molecule, lipoprotein- associated coagulation inhibitor, antithrombin III variant, plasminogen activator inhibitor- 1, Upoprotein lipase, alpha-2-macroglobulin, apolipoprotein Al, apolipoprotein All, apolipoprotein B-100, Upoprotein apoCII, pre- apolipoprotein CM, apoUpoprotein apo C-IV, macrophage scavenger receptor type I, human antigen CD36 gene, serum amyloid P component, carboxyl ester lipase gene, paraoxonase 1, paraoxonase 2, paraoxonase 3, LDL-receptor related protein, hepatic triglyceride Upase, 3-hydroxy-3- methylglutaryl coenzyme A synthase, very low density Upoprotein receptor, microsomal triglyceride transfer protein, periUpin, endotheUn-1, endothelin receptor A, interleukin 6, interleukin 1, complement protein C8 alpha, complement component C9, prostaglandin D2 synthase, annexin II/lipocortinII, annexin I/lipocortin, prostaglandin-endoperoxide synthase 2, insulin-like growth factor binding protein- 1 , secreted protein, acidic and rich in cysteine, human NF-kappa-B transcription factor, angiotensinogen, nitric oxide synthase 3, and nitric oxide synthase 2. Typically, this means that the known gene is expressed at higher levels (i.e., has more abundant transcripts) in atherosclerotic lesions than in normal or non-diseased arterial intima or any other tissue. "Ligand" refers to any molecule, agent, or compound which will bind specifically to a complementary site on a polynucleotide or polypeptide. Such ligands stabiUze or modulate the activity of polynucleotides or polypeptides of the invention. For example, ligands are libraries of inorganic and organic molecules or compounds such as nucleic acids, proteins, peptides, carbohydrates, fats, and lipids. "NSEQ" refers generally to a polynucleotide sequence of the present invention, including SEQ ID NO: 1 -34. "PSEQ" refers generally to a polypeptide sequence of the present invention, including SEQ ID NO:35. A "fragment" refers to a nucleic acid sequence that is preferably at least 20 nucleotides in length, more preferably 40 nucleotides, and most preferably 60 nucleotides in length, and encompasses, for example, fragments consisting of 1-50, 51-400, 401-4000, 4001-12,000 nucleotides, and the like, of SEQ ID NO:l-34. "Gene" refers to the partial or complete coding sequence of a gene including 5' or 3' untranslated regions. The gene may be in a sense or antisense (complementary) orientation. "Polynucleotide" refers to a nucleic acid, nucleic acid sequence, oligonucleotide, nucleotide, or any fragment thereof. It may be DNA or RNA of genomic or synthetic oπgin, double-stranded or single-stranded, and combined with carbohydrate, lipids, protein or other matenals to perform a particular activity or form a useful composition. "Oligonucleotide" is substantially equivalent to the terms amphmer, pπmer, oligomer, element, and probe. "Polypeptide" refers to an amino acid, amino acid sequence, oligopeptide, peptide, or protein or portions thereof whether naturally occurnng or synthetic. A "portion" refers to peptide sequence which is preferably at least 5 to about 15 amino acids in length, most preferably at least 10 am o acids long, and which retains some biological or immunological activity of, for example, a portion of SEQ ID NO:35. "Sample" is used in its broadest sense. A sample containing nucleic acids may comprise a bodily fluid: an extract from a cell, chromosome, organelle, or membrane isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue; a tissue print; and the like. "Substantially purified" refers to a nucleic acid or an amino acid sequence that is removed from its natural environment and that is isolated or separated, and is at least about 60% free, preferably about 75% free, and most preferably about 90% free, from other components with which it is naturally present. "Substrate" refers to any rigid or semi-ngid support to which polynucleotides or polypeptides are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a vanety of surface forms including wells, trenches, pins, channels and pores. A " vanant" refers to a polynucleotide or polypeptide whose sequence diverges from SEQ ID NO 1-35 Polynucleotide sequence divergence may result from mutational changes such as deletions, additions, and substitutions of one or more nucleotides; it may also be introduced to accommodate differences in codon usage. Each of these types of changes may occur alone, or in combination, one or more times in a given sequence. THE INVENTION The present invention encompasses a method for identifying biomolecules that are associated with a specific disease, regulatory pathway, subcellular compartment, cell type, tissue type, or species. In particular, the method identifies polynucleotides useful in diagnosis, prognosis, treatment, prevention, and evaluation of therapies for diseases associated with atherosclerosis including, but not limited to, stroke, myocardial infarction, hypertension, transient cerebral ischemia, mesentenc ischemia, coronary artery disease, angina pectoπs, peripheral vascular disease, intermittent claudication, renal artery stenosis, and hypertension The method entails first identifying polynucleotides that are expressed in a plurahty of cDNA hbranes. The identified polynucleotides include genes of known or unknown function which are expressed in a specific disease process, subcellular compartment, cell type, tissue type, or species. The expression patterns of the genes with known function are compared with those of genes with unknown function to determine whether a specified coexpression probability threshold is met. Through this comparison, a subset of the polynucleotides having a high coexpression probability with the known genes can be identified. The high coexpression probability correlates with a particular coexpression probability threshold which is preferably less than 0.001 and more preferably less than 0.00001. The polynucleotides oπginate from cDNA hbranes denved from a variety of sources including, but not limited to, eukaryotes such as human, mouse, rat, dog, monkey, plant, and yeast; prokaryotes such as bacteria; and viruses. These polynucleotides can also be selected from a vanety of sequence types including, but not limited to, expressed sequence tags (ESTs), assembled polynucleotide sequences, full length gene coding regions, promoters, lntrons, enhancers, 5' untranslated regions, and 3' untranslated regions. To have statistically significant analytical results, the polynucleotides need to be expressed in at least three cDNA hbranes The cDNA hbranes used in the coexpression analysis of the present invention can be obtained from adrenal gland, biliary tract, bladder, blood cells, blood vessels, bone marrow, brain, bronchus, cartilage, chromaffin system, colon, connective tissue, cultured cells, embryomc stem cells, endocnne glands, epithelium, esophagus, fetus, ganglia, heart, hypothalamus, immune system, intestine, islets of Langerhans, kidney, larynx, liver, lung, lymph, muscles, neurons, ovary, pancreas, perns, penpheral nervous system, phagocytes, pituitary, placenta, pleurus, prostate, salivary glands, seminal vesicles, skeleton, spleen, stomach, testis, thymus, tongue, ureter, uterus, and the Uke. The number of cDNA hbranes selected can range from as few as 3 to greater than 10,000. Preferably, the number of the cDNA hbranes is greater than 500. In a preferred embodiment, genes are assembled from related sequences, such as assembled sequence fragments denved from a single transcnpt. Assembly of the sequences can be performed using sequences of various types including, but not limited to, ESTs, extensions, or shotgun sequences. In a most prefened embodiment, the polynucleotide sequences are derived from human sequences that have been assembled using the algonthm disclosed in "Database and System for Storing, Comparing and Displaying Related Biomolecular Sequence Information", Lincoln et al. Senal No:60/079,469, filed March 26, 1998, incorporated herein by reference. Experimentally, differential expression of the polynucleotides can be evaluated by methods including, but not limited to, differential display by spatial immobilization or by gel electrophoresis, genome mismatch scanning, representational difference analysis, and transcript imaging. Additionally, differential expression can be assessed by microanay technology. These methods may be used alone or in combination. Known atherosclerosis-associated genes are selected based on the use of these genes as diagnostic or prognostic markers or as therapeutic targets. The procedure for identifying novel genes that exhibit a statistically significant coexpression pattern with known atherosclerosis-associated genes is as follows. First, the presence or absence of a gene in a cDNA library is defined: a gene is present in a cDNA library when at least one cDNA fragment corresponding to that gene is detected in a cDNA sample taken from the Ubrary, and a gene is absent from a Ubrary when no conesponding cDNA fragment is detected in the sample. Second, the significance of gene coexpression is evaluated using a probability method to measure a due-to-chance probability of the coexpression. The probability method can be the Fisher exact test, the chi-squared test, or the kappa test. These tests and examples of their applications are well known in the art and can be found in standard statistics texts (Agresti (1990) Categorical Data Analysis, John Wiley & Sons, New York NY; Rice (1988) Mathematical Statistics and Data Analysis. Duxbury Press, Pacific Grove CA). A Bonferroni correction (Rice, supra, p. 384) can also be applied in combination with one of the probabiUty methods for conecting statistical results of one gene versus multiple other genes. In a preferred embodiment, the due-to-chance probability is measured by a Fisher exact test, and the threshold of the due-to-chance probability is set preferably to less than 0.001 , more preferably to less than 0.00001. To determine whether two genes, A and B, have similar coexpression patterns, occurrence data vectors can be generated as illustrated in Table 1. The presence of a gene occurring at least once in a library is indicated by a one, and its absence from the library, by a zero. For a given pair of genes, the occurrence data in Table 1 can be summarized in a 2 x 2 contingency table. Table 2. Contin ency table for co-occurrences of genes A and B Table 2 presents co-occunence data for gene A and gene B in a total of 30 libraries. Both gene A and gene B occur 10 times in the libraries. Table 2 summarizes and presents: 1) the number of times gene A and B are both present in a Ubrary; 2) the number of times gene A and B are both absent in a library, 3) the number of times gene A is present, and gene B is absent; and 4) the number of times gene B is present, and gene A is absent. The upper left entry is the number of times the two genes co-occur in a library, and the middle nght entry is the number of times neither gene occurs in a library. The off diagonal entnes are the number of times one gene occurs, and the other does not. Both A and B are present eight times and absent 18 times. Gene A is present, and gene B is absent, two times: and gene B is present, and gene A is absent, two times. The probability ("p- value") that the above association occurs due to chance as calculated using a Fisher exact test is 0.0003. Associations are generally considered significant if a p-value is less than 0.01 (Agresti, supra; Rice, supra). This method of estimating the probability for coexpression of two genes makes several assumptions. The method assumes that the hbranes are independent and are identically sampled. However, in practical situations, the selected cDNA libraries are not entirely independent, because more than one library may be obtained from a single subject or tissue. Nor are they entirely identically sampled, because different numbers of cDNAs may be sequenced from each library. The number of cDNAs sequenced typically ranges from 5,000 to 10,000 cDNAs per library. In addition, because a Fisher exact coexpression probability is calculated for each gene versus 45,233 other assembled genes, a Bonfenoni conection for multiple statistical tests is used. The present invention identifies 34 novel atherosclerosis-associated polynucleotides that exhibit strong association with genes known to be specific to atherosclerosis. The results presented in Table 4 show that the expression of the 34 novel atherosclerosis-associated polynucleotides has direct or indirect association with the expression of known atherosclerosis-associated genes Therefore, the novel atherosclerosis-associated polynucleotides can potentially be used in diagnosis, treatment, prognosis, or prevention of diseases associated with atherosclerosis or in the evaluation of therapies for atherosclerosis. Further, the gene products of the 34 novel atherosclerosis-associated polynucleotides are either potential therapeutics or targets of therapeutics against atherosclerosis. Therefore, in one embodiment, the present invention encompasses a polynucleotide sequence compπsing the sequence of SEQ ID NO: 1-34 These 34 polynucleotides are shown by the method of the present invention to have strong coexpression association with known atherosclerosis-associated genes and with each other. The invention also encompasses a vaπant of the polynucleotide sequence, its complement, or 18 consecutive nucleotides of a sequence provided in the above described sequences. Variant polynucleotide sequences typically have at least about 75%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to NSEQ NSEQ or the encoded PSEQ may be used to search against the GenBank primate (pπ), rodent (rod), mammalian (mam), vertebrate (vrtp), and eukaryote (eukp) databases, SwissProt, BLOCKS (Bairoch et al. (1997) Nucleic Acids Res 25:217-221), PFAM, and other databases that contain previously identified and annotated motifs, sequences, and gene functions. Methods that search for pnmary sequence patterns with secondary structure gap penalties (Smith et al. (1992) Prot Eng 5.35-51) as well as algorithms such as Basic Local Alignment Search Tool (BLAST; Altschul (1993) J Mol Evol 36.290-300, Altschul et al- (1990) J Mol Biol 215 403-410), BLOCKS (Hemkoff and Hemkoff (1991) Nucleic Acids Res 19.6565-6572), Hidden Markov Models (HMM; Eddy (1996) Cur Opin Str Biol 6.361-365, Sonnhammer et al. (1997) Proteins 28.405-420), and the like, can be used to manipulate and analyze nucleotide and amino acid sequences. These databases, algorithms and other methods are well known in the art and are descnbed in Ausubel et al. (1997; Short Protocols in Molecular Biology. John Wiley & Sons, New York NY, unit 7.7) and in Meyers (1995; Molecular Biology and Biotechnology, Wiley VCH, New York NY, p 856-853) Also encompassed by the invention are polynucleotide sequences that are capable of hybndizing to SEQ ID NO.1-34, and fragments thereof under stπngent conditions. Stringent conditions can be defined by salt concentration, temperature, and other chemicals and conditions well known in the art. Conditions can be selected, for example, by varying the concentrations of salt in the prehybπdization. hybndization, and wash solutions or by varying the hybndization and wash temperatures. With some substrates, the temperature can be decreased by adding formamide to the prehybndization and hybridization solutions. Hybndization can be performed at low stπngency, with buffers such as 5xSSC with 1% sodium dodecyl sulfate (SDS) at 60°C, which permits complex formation between two nucleic acid sequences that contain some mismatches. Subsequent washes are performed at higher stnngency with buffers such as 0 2xSSC with 0 1% SDS at either 45 °C (medium stringency) or 68°C (high stringency), to maintain hybridization of only those complexes that contain completely complementary sequences. Background signals can be reduced by the use of detergents such as SDS, Sarcosyl, or TRITON X-100 (Sigma-Aldnch, St. Louis MO) , and or a blocking agent, such as salmon sperm DNA. Hybndization methods are descnbed in detail in Ausubel (supra, umts 2.8-2.11, 3 18-3.19 and 4-6-4.9) and Sambrook et al (1989, Molecular Clomng, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY) NSEQ can be extended utilizing a partial nucleotide sequence and employing vaπous PCR- based methods known in the art to detect upstream sequences such as promoters and other regulatory elements. (See, e.g., Dieffenbach and Dveksler (1995) PCR Pπmer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY) Additionally, one may use an XL-PCR kit (PE Biosystems, Foster City CA), nested pπmers, and commercially available cDNA libraries (Life Technologies, Rockville MD) or genomic Ubranes (Clontech, Palo Alto CA) to extend the sequence. For all PCR-based methods, pπmers may be designed using commercially available software, such as OLIGO 4.06 Pπmer Analysis software (National Biosciences, Plymouth MN) or another program, to be about 18 to 30 nucleotides in length, to have a GC content of about 50%, and to form a hybπdization complex at temperatures of about 68°C to 72°C. In another aspect of the invention, NSEQ can be cloned in recombmant DNA molecules that direct the expression of PSEQ, or structural or functional portions thereof, in host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express the polypeptide encoded by NSEQ. The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter the nucleotide sequences for a vanety of purposes including, but not limited to, modification of the clomng, processing, and or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, ohgonucleotide- mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice vaπants, and so forth. In order to express a biologically active polypeptide, NSEQ, or deπvatives thereof, may be inserted into an expression vector, i.e., a vector which contains the elements tor transcπptional and translational control of the inserted coding sequence in a particular host. These elements include regulatory sequences, such as enhancers, constitutive and mducible promoters, and 5' and 3' untranslated regions. Methods which are well known to those skilled in the art may be used to construct such expression vectors. These methods include in vitro recombmant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra; and Ausubel, supra). A vanety of expression vector/host cell systems may be utilized to express NSEQ. These include, but are not limited to, microorganisms such as bactena transformed with recombmant bactenophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with baculovirus vectors; plant cell systems transformed with viral or bacteπal expression vectors; or animal cell systems. For long term production of recombmant proteins in mammalian systems, stable expression in cell Unes is prefeπed. For example, NSEQ can be transformed into cell Unes using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable or visible marker gene on the same or on a separate vector. The invention is not to be limited by the vector or host cell employed. In general, host cells that contain NSEQ and that express PSEQ may be identified by a vanety of procedures known to those of skill in the art. These procedures include, but are not Umited to, DNA- DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or amino acid sequences. Immunological methods for detecting and measuring the expression of PSEQ using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). Host cells transformed with NSEQ may be cultured under conditions for the expression and recovery of the polypeptide from cell culture. The polypeptide produced by a transgenic cell may be secreted or retained intraceilularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing NSEQ may be designed to contain signal sequences which direct secretion of the polypeptide through a prokaryotic or eukaryotic cell membrane. In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylaϋon, carboxylation, glycosylation, phosphorylation, hpidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and charactenstic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the ATCC (Manassas VA) and may be chosen to ensure the correct modification and processing of the expressed polypeptide. In another embodiment of the invention, natural, modified, or recombmant nucleic acid sequences are hgated to a heterologous sequence resulting in translation of a fusion polypeptide containing heterologous polypeptide moieties in any of the aforementioned host systems. Such heterologous polypeptide moieties facilitate puπfication of fusion polypeptides using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase, maltose binding protein, thioredoxin, calmodulin binding peptide, 6-Hιs, FLAG, c-myc, hemaglutinin, and monoclonal antibody epitopes. In another embodiment, the nucleic acid sequences are synthesized, in whole or in part, using chemical or enzymatic methods well known in the art (Caruthers et al. (1980) Nucleic Acids Symp Ser (7) 215-233; Ausubel, supra). For example, peptide synthesis can be performed using vanous sohd-phase techniques (Roberge et al. (1995) Science 269:202-204), and machines such as the ABI 431 A Peptide synthesizer (PE Biosystems) can be used to automate synthesis. If desired, the ammo acid sequence may be altered during synthesis and/or combined with sequences from other proteins to produce a vanant protein. In another embodiment, the invention entails a substantially punfied polypeptide compπsing the amino acid sequence of SEQ ID NO.35 and fragments thereof SCREENING, DIAGNOSTICS AND THERAPEUTICS The polynucleotide sequences can be used in diagnosis, prognosis, treatment, prevention, and selection and evaluation of therapies for atherosclerosis including, but not limited to, stroke, myocardial infarction, hypertension, transient cerebral ischemia, mesentenc ischemia, coronary artery disease, angina pectons, penpheral vascular disease, intermittent claudication, renal artery stenosis, and hypertension. The polynucleotide sequences may be used to screen a library of molecules for specific binding affinity. The assay can be used to screen a library of DNA molecules, RNA molecules, PNAs, peptides, πbozymes, antibodies, agomsts, antagonists, immunoglobulins, inhibitors, proteins including transcπption factors, enhancers, repressors, and drugs and the like which regulate the activity of the polynucleotide sequence in the biological system. The assay involves providing a library of molecules, combimng the polynucleotide sequence or a fragment thereof with the library of molecules under conditions suitable to allow specific binding, and detecting specific binding to identify at least one molecule which specifically binds the polynucleotide sequence. Similarly the polypeptide or a portion thereof may be used to screen hbranes of molecules in any of a vanety of screemng assays. The portion of the polypeptide employed in such screening may be free in solution, affixed to an abiotic or biotic substrate (e.g. borne on a cell surface), or located intracellularly Specific binding between the polypeptide and molecule may be measured The assay can be used to screen a library of DNA molecules, RNA molecules, PNAs, peptides, mimetics, πbozymes, antibodies, agomsts, antagonists, immunoglobuUns, inhibitors, peptides, polypeptides, drugs and the like, which specifically bind the polypeptide. One method for high throughput screemng using very small assay volumes and very small amounts of test compound is descπbed in Burbaum et al. USPN 5,876,946, incorporated herein by reference, which screens large numbers of molecules for enzyme inhibition or receptor binding. In one prefened embodiment, the polynucleotide sequences are used for diagnostic purposes to determine the absence, presence, and excess expression of the polypeptide. The polynucleotides may be at least 18 nucleotides long and consist of complementary RNA and DNA molecules, branched nucleic acids, and/or peptide nucleic acids (PNAs). In one alternative, the polynucleotides are used to detect and quantify gene expression m samples in which expression of NSEQ is conelated with disease. In another alternative, NSEQ can be used to detect genetic polymorphisms associated with a disease. These polymorphisms may be detected in the transcript cDNA. The specificity of the probe is determined by whether it is made from a umque region, a regulatory region, or from a conserved motif. Both probe specificity and the stnngency of diagnostic hybπdization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occumng, exactly complementary sequences, allelic vanants, or related sequences. Probes designed to detect related sequences should preferably have at least 75% sequence identity to any of the polynucleotides encoding PSEQ Methods for producing hybridization probes include the clomng of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by adding RNA polymerases and labeled nucleotides. Hybπdization probes may incorporate nucleotides labeled by a vanety of reporter groups including, but not limited to, radionuchdes such as 32 P or 35 S, enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, fluorescent labels, and the like. The labeled polynucleotide sequences may be used in Southern or northern analysis, dot blot, or other membrane-based technologies, in PCR technologies; and in microanays utilizing samples from subjects to detect altered PSEQ expression. NSEQ can be labeled by standard methods and added to a sample from a subject under conditions for the formation and detection of hybπdization complexes. After incubation the sample is washed, and the signal associated with hybπd complex formation is quantitated and compared with a standard value Standard values are derived from any control sample, typically one that is free of the suspect disease. If the amount of signal in the subject sample is altered in compaπson to the standard value, then the presence of altered levels ot expression in the sample indicates the presence of the disease Qualitative and quantitative methods for companng the hybridization complexes formed in subject samples with previously established standards are well known m the art. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in cUmcal trials, or to momtor the treatment of an individual subject Once the presence of disease is established and a treatment protocol is initiated, hybridization or amplification assays can be repeated on a regular basis to determine if the level of expression in the subject begins to approximate that which is observed in a healthy subject. The results obtained from successive assays may be used to show the efficacy of treatment over a penod ranging from several days to many years The polynucleotides may be used for the diagnosis of a variety of diseases associated with atherosclerosis. These include, but are not limited to, stroke, myocardial infarction, hypertension, transient cerebral ischemia, mesentenc ischemia, coronary artery disease, angina pectons, penpheral vascular disease, intermittent claudication, renal artery stenosis, and hypertension. The polynucleotides may also be used as targets in a microarray. The microarray can be used to momtor the expression patterns of large numbers of genes simultaneously and to identify sphce vanants, mutations, and polymorphisms. Information derived from analyses of the expression patterns may be used to determine gene function, to understand the genetic basis of a disease, to diagnose a disease, and to develop and momtor the activities of therapeutic agents used to treat a disease. Microarrays may also be used to detect genetic diversity, single nucleotide polymoφhisms which may characteπze a particular population, at the genome level. In yet another alternative, polynucleotides may be used to generate hybndization probes useful in mapping the naturally occurnng genomic sequence. Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techmques and genetic map data as descπbed in Heinz-Ulπch et al (In. Meyers, supra, pp. 965-968). In another embodiment, antibodies or Fabs compnsing an antigen binding site that specifically binds PSEQ may be used for the diagnosis of diseases charactenzed by the over-or-under expression of PSEQ. A vanety of protocols for measunng PSEQ, including ELISAs, RIAs, and FACS, are well known in the art and provide a basis for diagnosing altered or abnormal levels of expression. Standard values for PSEQ expression are established by combimng samples taken from healthy subjects, preferably human, with antibody to PSEQ under conditions for complex formation The amount of complex formation may be quantitated by vaπous methods, preferably by photometric means. Quantities of PSEQ expressed in disease samples are compared with standard values. Deviation between standard and subject values establishes the parameters for diagnosing or monitoring disease. Alternatively, one may use competitive drug screemng assays in which neutraUz g antibodies capable of binding PSEQ specifically compete with a test compound for binding the polypeptide. Antibodies can be used to detect the presence of any peptide which shares one or more antigemc determinants with PSEQ. In one aspect, the anti-PSEQ antibodies of the present invention can be used for treatment or momtonng therapeutic treatment for atherosclerosis. In another aspect, the NSEQ, or its complement, may be used therapeutically for the puφose of expressing mRNA and polypeptide, or conversely to block transcnption or translation of the mRNA. Expression vectors may be constructed using elements from retroviruses, adenovrruses, heφes or vaccima viruses, or bactenal plasmids, and the like. These vectors may be used for delivery of nucleotide sequences to a particular target organ, tissue, or cell population. Methods well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences or their complements. (See, e.g., Mauhk et al. (1997) Molecular Biotechnology. Therapeutic Applications and Strategies, Wiley-Liss, New York NY.) Alternatively, NSEQ, or its complement, may be used for somatic cell or stem cell gene therapy Vectors may be introduced in vivo, in vitro, and ex vivo For ex vivo therapy, vectors are introduced into stem cells taken from the subject, and the resulting transgenic cells are clonally propagated for autologous transplant back into that same subject. Delivery of NSEQ by transfection, hposome injections, or polycatiomc amino polymers may be achieved using methods which are well known in the art and descnbed in Goldman et al (1997; Nature Biotechnol 15.462-466). Additionally, endogenous NSEQ expression may be inactivated using homologous recombination methods which insert an inactive gene sequence into the coding region or other targeted region of NSEQ. (See, e.g Thomas et al. (1987) Cell 51.503-512 ) Vectors containing NSEQ can be transformed into a cell or tissue to express a missing polypeptide or to replace a nonfunctional polypeptide. Similarly a vector constructed to express the complement of NSEQ can be transformed into a cell to downregulate the overexpression of PSEQ Complementary or antisense sequences may consist of an oligonucleotide denved from the transcription initiation site, nucleotides between about positions -10 and +10 from the ATG are prefened Similarly, inhibition can be achieved using triple helix base-paiπng methodology Tπple helix painng is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcnption factors, or regulatory molecules Recent therapeutic advances using tnplex DNA have been described in the literature (See, e g , Gee et al In Huber and Can (1994) Molecular and Immunologic Approaches, Futura Publishing Co , Mt Kisco NY, pp 163-177 ) Ribozymes, enzymatic RNA molecules, may also be used to catalyze the cleavage of mRNA and decrease the levels of particular mRNAs, such as those compπsing the polynucleotide sequences of the invention (See, e g , Rossi (1994) Cunent Biology 4 469-471 ) Ribozymes may cleave mRNA at specific cleavage sites Alternatively, πbozymes may cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA The construction and production of πbozymes is well known in the art and is described in Meyers (supra) RNA molecules may be modified to increase lntracellular stability and half-Ufe Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages within the backbone of the molecule Alternatively, nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of ademne, cytidine, guamne, thymine, and undine which are not as easily recogmzed by endogenous endonucleases, may be included Further, an antagonist, or an antibody that binds specifically to PSEQ may be administered to a subject to treat or prevent atherosclerosis The antagonist, antibody, or fragment may be used directly to inhibit the activity of the polypeptide or indirectly to deUver a therapeutic agent to cells or tissues which express the PSEQ An immunoconjugate compnsing a PSEQ binding site of the antibody or the antagonist and a therapeutic agent may be administered to a subject m need to treat or prevent disease The therapeutic agent may be a cytotoxic agent selected from a group including, but not limited to, abπn, πcin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincnstine, vinblastine, colcmcine, dihydroxy anthracin dione, actinomycin D, diphtena toxin, Pseudomonas exotoxin A and 40, radioisotopes, and glucocorticoid Antibodies to PSEQ may be generated using methods that are well known in the art Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression Ubrary Neutralizing antibodies, such as those which inhibit dimer formation, are especially prefened for therapeutic use Monoclonal antibodies to PSEQ may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture These include, but are not limited to, the hybπdoma, the human B-cell hybndoma, and the EB V-hybπdoma techmques. In addition, techniques developed for the production of chimenc antibodies can be used. (See, e.g., Pound (1998) Immunochemical Protocols, Methods Mol Biol Vol 80). Alternatively, techmques described for the production of single chain antibodies may be employed. Fabs which contain specific binding sites for PSEQ may also be generated. Vaπous immunoassays may be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometπc assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art Yet further, an agomst of PSEQ may be administered to a subject to treat or prevent a disease associated with decreased expression, longevity or activity of PSEQ. An additional aspect of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable earner, for any of the therapeutic applications discussed above. Such pharmaceutical compositions may consist of PSEQ or antibodies, mimetics, agomsts, antagonists, or inhibitors of the polypeptide. The compositions may be administered alone or in combination with at least one other agent, such as a stabihzing compound, which may be administered m any stenle, biocompatible pharmaceutical earner including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be admimstered to a subject alone or in combination with other agents, drugs, or hormones. The pharmaceutical compositions utilized in this invention may be admimstered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, lntrameduUary, intrathecal, lntraventricular, transdermal, subcutaneous, mtraperitoneal, mtranasal, enteral, topical, subhngual, or rectal means. In addition to the active ingredients, these pharmaceutical compositions may contain pharmaceutically-acceptable earners comprising excipients and auxihanes which facihtate processing of the active compounds into preparations which can be used pharmaceutically Further details on techmques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. A therapeutically effective dose refers to that amount of active ingredient which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with expenmental animals, such as by calculating and contrasting the ED 50 (the dose therapeutically effective in 50% of the population) and LD, 0 (the dose lethal to 50% of the population) statistics. Any of the therapeutic compositions descπbed above may be applied to any subject in need of such therapy, including, but not limited to, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans EXAMPLES It is to be understood that this invention is not limited to the particular devices, machines, materials and methods descπbed. Although particular embodiments are descnbed, equivalent embodiments may be used to practice the invenuon. The descnbed embodiments are provided to illustrate the invention and are not intended to limit the scope of the invention which is limited only by the appended claims. I cDNA Library Construction The cDNA library SMCCNOS01 was selected as an example to demonstrate the construction of cDNA libraries from which the polynucleotides associated with known atherosclerosis-associated genes were derived The SMCCNOS01 subtracted coronary artery smooth muscle cell library was constructed using 7 56 x 10 6 clones from the SMCCNOT02 library and was subjected to two rounds of subtraction hybndization for 48 hours with 6.12 x 10 6 clones from SMCCNOTOl . The SMCCNOT02 library was constructed using RNA isolated from coronary artery smooth muscle cells removed from a 3-year-old Caucasian male. The cells were treated for 20 hours with TNFα and IL-lβ at lOng ml each. The SMCCNOTOl was constructed using RNA isolated from untreated coronary artery smooth muscle cells from the same donor. Subtractive hybπdization conditions were based on the methodologies of Swaroop et al. (1991 ; Nucleic Acids Res 19 1954) and Bonaldo et al- (1996; Genome Res 6.791). For both cDNA libraries, SMCCNOTOl and SMCCNOT02, the frozen coronary artery smooth muscle cells (50-100 mg) were homogemzed in GTC buffer (4.0M guanidme thiocyanate, 0.1M Tπs- HC1 pH 7 5. 1 % 2-mercaptoethanol). Two volumes of binding buffer (04M LiCl, 0.1M Tπs-HCl pH 7.5, 0.02M EDTA) were added, and the resulting mixture was vortexed at 13,000 φra The supernatant was removed and combined with OUgo d(T) 25 bound streptavidm particles (MPG). After rotation at room temperature, the mRNA-Ohgo d(T) 25 bound streptavidm particles were separated from the supernatant, washed twice with hybndization buffer I (0.15M NaCl, 0.01M Tris-HCl pH8.0, ImM EDTA, 0.1 % lauryl sarcosinate) using magnetic separation at each step to remove the supernatant from the particles. Bound mRNA was eluted from the particles with release solution and heated to 65 °C. The supernatant containing eluted mRNA was magnetically separated from the particles and used to construct the cDNA hbranes. The RNA was used for cDNA synthesis and construction of the cDNA library according to the recommended protocols in the SUPERSCRIPT plasπud system (Life Technologies). The cDNAs were fractionated on a SEPHAROSE CL4B column (Amersham Pharmacia Biotech (APB), Piscataway NJ), and those cDNAs exceeding 400 bp were Ugated into pINCY plasmid (Incyte Genomics, Palo Alto CA). Recombmant plasmids were transformed into DH5 competent cells or ELECTROMAX cells (Life Technologies) II Isolation and Sequencing of cDNA Clones Plasmid DNA was released from the cells and purified using the REAL PREP 96 plasmid kit 5 (Qiagen, Valencia CA). The recommended protocol was employed except for the following changes. 1) the bacteria were cultured in 1 ml of sterile TERRIFIC BROTH media (BD Biosciences, Sparks MD) with carbenicillin at 25 mg/L and glycerol at 0.4% ; 2) after inoculation, the cells were cultured for 19 hours and then lysed with 0.3 ml of lysis buffer, and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml distilled water, and samples were transfened to a 10 96-well block for storage at 4° C. The cDNAs were prepared using a MICROLAB 2200 System (Hamilton, Reno NV) in combination with the DNA ENGINE thermal cycler (MJ Research, Watertown MA). cDNAs were sequenced by the method of Sanger and Coulson (1975; J Mol Biol 94.441f) using ABI PRISM 377 (PE Biosystems) or MEGABACE 1000 sequencing systems (APB). 15 Most of the sequences disclosed herein were sequenced using standard ABI protocols and kits (PE Biosystems) at solution volumes of 0.25x -1.Ox concentrations. In the alternative, some of the sequences disclosed herein were sequenced using solutions and dyes from APB. HI Selection, Assembly, and Characterization of Sequences The sequences used for co-expression analysis were assembled from EST sequences, 5' and 3' 20 longread sequences, and full length coding sequences. Selected assembled sequences were expressed in at least three cDNA hbranes. The assembly process is descnbed as follows. EST sequence chromatograms were processed and venfied. Quality scores were obtained using PHRED (Ewing et al (1998) Genome Res 8 175-185, Ewing and Green (1998) Genome Res 8.186-194), and edited sequences were loaded into a relational 25 database management system (RDBMS). The sequences were clustered using BLAST with a product score of 50. All clusters of two or more sequences created a bin which represents one transcribed gene Assembly of the component sequences within each bin was performed using a modification of Phrap, a publicly available program for assembling DNA fragments (Green, P. Umversity of Washington, Seattle WA). Bins that showed 82% identity from a local pair-wise ahgnment between 30 any of the consensus sequences were merged. Bins were annotated by screemng the consensus sequence in each bin against public databases, such as GBpπ and GenPept from NCBI. The annotation process involved a FASTn screen against the GBpn database in GenBank. Those hits with a percent identity of greater than or equal to 75% and an alignment length of greater than or equal to 100 base pairs were recorded as homolog hits. The residual 35 unannotated sequences were screened by FASTx against GenPept Those hits with an E value of less than or equal to 10 were recorded as homolog hits Sequences were then reclustered using BLASTn and Cross-Match, a program for rapid amino acid and nucleic acid sequence companson and database search (Green, supra), sequentially Any BLAST alignment between a sequence and a consensus sequence with a score greater than 150 was realigned using cross-match The sequence was added to the bin whose consensus sequence gave the highest Smith-Waterman score (Smith et al (1992) Incyte Genoπucs 5 35-51) amongst local alignments with at least 82% identity Non-matching sequences were moved into new bins, and assembly processes were repeated IV Coexpression Analyses of Atherosclerosis-Associated Genes Sixty-six known atherosclerosis-associated genes were selected to identify novel genes that are closely associated with atherosclerosis The known atherosclerosis-associated genes which were examined in this analysis and bπef descriptions of their functions are listed in Table 3 Table 3. Descriptions of Known Atherosclerosis-Associated Genes GENE DESCRIPTION AND REFERENCES Mediates basal vasodilation. Regulates the production of nitric oxide, an important signal transduction component and scavenger of reactive oxygen Nitric Oxide species. NOS2, known as inducible NOS is expressed in most cells only after Synthase 2 induction by immunologic and inflammatory stimuli, and is upregulated in (NOS2) pathological conditions such as atherosclerosis (Dusting et al. (1998) Clin Expt Pharmacol Phisiol 25 :S 34-41) 5 From a total of 45,233 assembled gene sequences, 34 novel genes were identified, SEQ ID NOs: 1-34, that show strong association with 66 known atherosclerosis-associated genes. Initially, the degree of association was measured by probabiUty values using a cutoff p value less than 0.00001. The sequences were further examined to ensure that the genes that passed the probability test had strong association with known atherosclerosis-associated genes. Details of the co-expression patterns for the 10 66 known and 34 novel atherosclerosis-associated polynucleotides are presented in Table 4. The entries in Table 4 are the negative log of the p-value (-log p) for the coexpression of the two genes. The novel atherosclerosis-associated polynucleotides identified are listed in the table by their SEQ ID NOs numbers, and the known genes, by their names or the abbreviations shown in Table 3. V Novel Genes Associated with Atherosclerosis 15 Using the co-expression analysis method, 34 novel atherosclerosis-associated polynucleotides were identified, SEQ ID NOs: 1-34, that exhibit strong association, or co-expression, with 66 known atherosclerosis-associated genes. Polynucleotides comprising the consensus sequences of SEQ ID NO: 1-34 of the present invention were first identified from Incyte bins and assembled as described in Example III. BLAST 20 and other motif searches were performed for SEQ ID NOs: 1-34 according to Example VI. The full length and 5 '-complete sequences were translated and sequence identity was sought with known sequences. SEQ ID NO:35 of the present invention was encoded by the nucleic acids of SEQ ID NO: 11. SEQ ID NO:35 has 366 amino acids which are encoded by SEQ ID NO:l 1. Motif analyses of SEQ ID 25 NO:35 shows one potential cAMP- and cGMP-dependent protein kinase phosphorylation sites at residue S343, two potential casein kinase II phosphorylation sites at residues S 179 and T351 , and four potential protein kinase C phosphorylation sites at residues T29, S85, T269, and T324. Additionally, SEQ ID NO:35 contains a potential sugar transport protein signature sequence from residues L201 to S217. 30 VI Homology Searching for Atherosclerosis- Associated Polynucleotides and Polypeptides The polynucleotide sequences, SEQ ID NO: 1-34, and polypeptide sequence, SEQ ID NO:35, were queried against databases derived from sources such as GenBank and SwissProt. These databases, which contain previously identified and annotated sequences, were searched for regions of similarity using BLAST (Altschul, supra). BLAST searched for matches and reported only those that satisfied the probability thresholds of 10 25 or less for nucleotide sequences and 10 8 or less for polypeptide sequences. The polypeptide sequence was also analyzed for known motif patterns using MOTIF ' S, SPSCAN, BLIMPS, and HMM-based protocols MOTIFS (Genetics Computer Group, Madison WI) searches polypeptide sequences for patterns that match those defined in the Prosite Dictionary of Protein Sites and Patterns (Bairoch, supra) and displays the patterns found and their conesponding literature abstracts. SPSCAN (Genetics Computer Group) searches for potential signal peptide sequences using a weighted matnx method (Nielsen et al. (1997) Prot Eng 10.1-6). Hits with a score of 5 or greater were considered. BLIMPS uses a weighted matrix analysis algonthm to search for sequence similarity between the polypeptide sequences and those contained in BLOCKS, a database consisting of short amino acid segments, or blocks of 3-60 amino acids in length, compiled from the PROSITE database (Hemkoff; supra. Bairoch, supra), and those m PRINTS, a protein fingeφπnt database based on non-redundant sequences obtained from sources such as SwissProt, GenBank, PIR, and NRL-3D (Attwood et al. (1997) J Chem Inf Comput Sci 37 417-424). For the puφoses of the present invention, the BLIMPS searches reported matches with a cutoff score of 1000 or greater and a cutoff probabihty value of 1.0 x 10 3 HMM-based protocols were based on a probabiUstic approach and searched for consensus primary structures of gene families in the protein sequences (Eddy, supra, Sonnhammer, supra) More than 500 known protein families with cutoff scores ranging from 10 to 50 bits were selected for use in this invention. VII Labeling of Probes and Hybridization Analyses Substrate Preparation Nucleic acids are isolated from a biological source and applied to a substrate for standard hybπdization protocols by one of the following methods A mixture of target nucleic acids, a restriction digest of genomic DNA, is fractionated by electtophoresis through an 0 7% agarose gel in lxTAE [Tπs-acetate-ethylenediamine tettaacetic acid (EDTA)] running buffer and transfened to a nylon membrane by capillary transfer using 20x saline sodium citrate (SSC). Alternatively, the target nucleic acids are individually hgated to a vector and inserted into bacterial host cells to form a library. Target nucleic acids are arranged on a substrate by one of the following methods. In the first method, bactenal cells contaimng individual clones are robotically picked and arranged on a nylon membrane The membrane is placed on bactenal growth medium, LB agar contaimng carbenicilhn, and incubated at 37°C for 16 hours Bacterial colonies are denatured, neutralized, and digested with proteinase K Nylon membranes are exposed to UV lnadiation in a STRATALINKER UV-crosshnker (Sttatagene) to cross-link DNA to the membrane. In the second method, target nucleic acids are amplified from bacteπal vectors by thirty cycles of PCR using primers complementary to vector sequences flanking the insert Amplified target nucleic acids are purified using SEPHACRYL-400 beads (APB). Purified target nucleic acids are robotically arrayed onto a glass microscope slide (Coming Science Products, Coming NY). The slide is previously coated with 005% aminopropyl silane (Sigma- Aldnch) and cured at 110°C. The anayed glass slide (microanay) is exposed to UV irradiation in a STRATALINKER UV-crosshnker (Sttatagene). Probe Preparation cDNA probes are made from mRNA templates. Five micrograms of mRNA is mixed with 1 μg random pπmer (Life Technologies), incubated at 70°C for 10 minutes, and lyophi zed. The lyophilized sample is resuspended in 50 μl of lx first strand buffer (cDNA Synthesis systems, Life Technologies) contaimng a dNTP mix, [α- 32 P]dCTP, dithiothreitol, and MMLV reverse ttanscπptase (Sttatagene), and incubated at 42°C for 1-2 hours. After incubation, the probe is diluted with 42 μl dH 2 0, heated to 95 °C for 3 minutes, and cooled on ice. mRNA in the probe is removed by alkaline degradation. The probe is neutralized, and degraded mRNA and unmcoφorated nucleotides are removed using a PROBEQUANT G-50 microcolumn (APB). Probes can be labeled with fluorescent markers, Cy3-dCTP or Cy5-dCTP (APB), in place of the radionucleotide, [ 32 P]dCTP. Hybndization Hybndization is earned out at 65 °C in a hybndization buffer contaimng 0.5 M sodium phosphate (pH 7.2), 7% SDS, and 1 mM EDTA. After the substrate is incubated in hybndization buffer at 65 °C for at least 2 hours, the buffer is replaced with 10 ml of fresh buffer contaimng the probes. After incubation at 65 °C for 18 hours, the hybndization buffer is removed, and the substrate is washed sequentially under increasingly stringent conditions, up to 40 mM sodium phosphate, 1 % SDS, 1 mM EDTA at 65 °C. To detect signal produced by a radiolabeled probe hybπdized on a membrane, the substrate is exposed to a PHOSPHORIMAGER cassette (APB), and the image is analyzed using IMAGEQUANT data analysis software (APB). To detect signals produced by a fluorescent probe hybπdized on a microanay, the substrate is examined by confocal laser microscopy, and images are collected and analyzed using GEMTOOLS gene expression analysis software (Incyte Genomics). VIII Complementary Polynucleotides Molecules complementary to the polynucleotide, or a fragment thereof, are used to detect, decrease, or inhibit gene expression. Although use of oligonucleotides compnsing from about 18 to about 60 base pairs is descπbed, the same procedure is used with larger or smaller fragments or their denvatives (PNAs). Oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and SEQ ID NO.1-34 or fragments thereof To inhibit transcnption by preventing promoter binding, a complementary oligonucleotide is designed to bind to the most umque 5 ' sequence, most preferably about 10 nucleotides before the imtiation codon of the open reading frame. To inhibit translation, a complementary oligonucleotide is designed to prevent πbosomal binding to the mRNA encoding the polypeptide. IX Production of Specific Antibodies The polypeptides encoded by SEQ ID NO: 1-34, or portions thereof, substantially purified using polyacrylamide gel electtophoresis or other punfication techmques, is used to immumze rabbits and to produce antibodies using standard protocols as descnbed in Pound (supra). Alternatively, the amino acid sequence is analyzed using LASERGENE software (DNASTAR, Madison WI) to determine regions of high lmmunogenicity, and a conesponding ohgopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of epitopes, such as those near the C-terminus or in hydrophihc regions are well descπbed in the art. Typically, oligopeptides 15 residues in length are synthesized using an ABI 431 A Peptide synthesizer (PE Biosystems) using fmoc-chemistry and coupled to keyhole limpet hemocyamn (KLH, Sigma- Aldnch) by reaction with N-maleimidobenzoyl-N-hydroxysuccimmide ester (Ausubel, supra) to increase lmmunogenicity. Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG X Screening Molecules for Specific Binding with the Polynucleotide or Polypeptide The polynucleotide, or fragments thereof, or the polypeptide, or portions thereof, are labeled with 32 P-dCTP, Cy3-dCTP, or Cy5-dCTP (APB), or with BIODIPY or FITC (Molecular Probes, Eugene OR), respectively Libranes of candidate molecules previously ananged on a substrate are incubated in the presence of labeled polynucleotide or polypeptide. After incubation under conditions for either a nucleic acid or amino acid sequence, the substrate is washed, and any position on the substrate retaining label, which indicates specific binding or complex formation, is assayed, and the binding molecule is identified. Data obtained using different concentrations of the polynucleotide or polypeptide are used to calculate affinity between the labeled nucleic acid or protein and the bound molecule.

Claims: What is claimed is: 1. A composition comprising an isolated polynucleotide that is coexpressed with one or more known atherosclerosis-associated genes in a plurality of samples and that is selected from the group consisting of (a) a nucleic acid sequence selected from SEQ ID NOs: 1-34, (b) a nucleic acid sequence encoding SEQ ID NO.35, (c) a nucleic acid sequence which is the complement of (a) or (b). 2. A polynucleotide compπsing the nucleic acid sequence of SEQ ID NO:8 or the complement thereof. 3. A composition comprising the polynucleotide of claim 1 4. A method of using a polynucleotide to screen a Ubrary of molecules or compounds to identify at least one ligand which specifically binds the polynucleotide, the method compπsing: (a) combimng the polynucleotide of claim 1 with a library of molecules or compounds under conditions to allow specific binding, and (b) detecting specific binding, thereby identifying a Ugand which specifically binds the polynucleotide. 5. The method of claim 4 wherein the library is selected from DNA molecules, RNA molecules, PNAs, mimetics, and proteins. 6. A ligand identified by the method of claim 4 which modulates the activity of the polynucleotide 7 A method of using a polynucleotide of to punfy a ligand which specifically binds the polynucleotide, the method compnsing: (a) combimng the polynucleotide of claim 1 with a sample under conditions to allow specific binding, (b) detecting specific binding between the polynucleotide and a Ugand, (c) recovering the bound polynucleotide, and (d) separating the polynucleotide from the ligand, thereby obtaimng punfied ligand. 8. A method for diagnosing a disease or condition associated with the altered expression of a polynucleotide that is coexpressed with one or more known atherosclerosis-associated genes in a sample , the method compnsing the steps of. (a) hybndizing the composition of claim 1 to a sample under conditions to form one or more hybπdization complexes, (b) detecting the hybridization complexes; and (c) comparing the levels of the hybridization complexes with the level of hybndization complexes in a non-diseased sample, wherein the altered level of hybπdization complexes compared with the level of hybndization complexes of a non-diseased sample indicates the presence of the disease or condition 9 An expression vector compnsing the polynucleotide of claim 2 10 A host cell comprising the expression vector of claim 9 11 A method for producing the polypeptide, the method compnsing (a) cultuπng the host cell of claim 10 under conditions for expression of the polypeptide, (b) recovenng the polypeptide from cell culture 12 A substantially punfied polypeptide comprising the product of a gene that is coexpressed with one or more known atherosclerosis-associated genes in a plurality of samples 13 The polypeptide of claim 12, compnsing a polypeptide sequence selected from (a) the polypeptides encoded by SEQ ID NOs 1-34, and (b) an ohgopeptide sequence comprising at least 6 sequential amino acids of the polypeptide sequence of a) 14 The polypeptide comprising the amino acid sequence of SEQ ID NO 35 15 A pharmaceutical composition compnsing a polypeptide of claim 12 and a pharmaceutical earner 16 A method for using a polypeptide to screen a library of molecules or compounds to identify at least one ligand which specifically binds the polypeptide, the method compnsing (a) combimng the polypeptide of claim 12 with the library of molecules or compounds under conditions to allow specific binding, and (b) detecting specific binding between the polypeptide and ligand, thereby identifying a ligand which specifically binds the polypeptide 17 The method of claim 16 wherein the library is selected from DNA molecules, RNA molecules, PNAs, mimetics, proteins, agomsts, antagonists, and antibodies 18 A ligand identified by the method of claim 16 which modulates the activity of the polypeptide 19 A method of using the polypeptide to purify a ligand from a sample, the method compnsing (a) combimng the polypeptide of claim 12 with a sample under conditions to allow specific binding, (b) detecting specific binding between the polypeptide and a ligand, (c) recovering the bound polypeptide, and (d) separating the polypeptide from the ligand, thereby obtaimng punfied ligand 20 A method for treating a disease associated with the altered expression of a gene that is coexpressed with one or more known atherosclerosis-associated genes m a subject in need, the method comprising the step of admimstering to the subject in need the pharmaceutical composition of claim 15 in an amount effective for tteating the disease.

Inventors: JONES KAREN ANN, VOLKMUTH WAYNE, WALKER MICHAEL G, JONES, KAREN, ANN, VOLKMUTH, WAYNE, WALKER, MICHAEL, G.
Applicants: INCYTE GENOMICS INC, JONES KAREN ANN, VOLKMUTH WAYNE, WALKER MICHAEL G, INCYTE GENOMICS, INC., JONES, KAREN, ANN, VOLKMUTH, WAYNE, WALKER, MICHAEL, G.
Application year: 2000
Main classification: C12N
IPC codes: A61K38, A61P9, A61P43, C07K14, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33, G01N37